Professor Cameron Turtle trained as a haemato-oncologist in Sydney, obtaining Fellowship of the Royal Australasian College of Physicians (RACP) and the Royal College of Pathologists of Australasia (RCPA) in 2000. He then completed a PhD in dendritic cell immunotherapy at the University of Queensland and a postdoctoral research fellowship in T cell immunotherapy at Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, USA. Cameron spent 17 years in Seattle and was Professor and Anderson Family Endowed Chair for Immunotherapy at FHCRC, Professor of Medicine at the University of Washington (UW), and Co-director of the Cancer Immunology Program of the Seattle Cancer Consortium. Cameron has served as Chair of the American Society of Hematology (ASH) Scientific Committee on Transplantation Biology and Cellular Therapies and is Co-Chair of the Cellular Immunotherapy for Cancer Working Committee of the Center for International Bone Marrow Transplantation Research (CIBMTR). In 2022 he was appointed Professor and CLEARbridge Chair of Cancer Immunotherapy in the Faculty of Medicine and Health at the University of Sydney. He has led clinical and laboratory research teams conducting multiple investigator-initiated phase 1/2 clinical trials of genetically modified cellular (CAR-T cell) immunotherapies for patients with haematologic malignancies. Cameron’s research laboratory in the Charles Perkins Center focuses on understanding the characteristics of distinct human T cell subsets, the development of novel tumour immunotherapies, and factors governing the immune response to cancer.